Patent details

Basic Information

Publication number:

92155

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP057797359

Legal Status:

Active

Application number:

92155

First applicant's nationality:

Procedural language:

French

Paediatric Extension

SPC Extension Filing Date:

29/09/2025

SPC Extension Agent Name:

OFFICE FREYLINGER S.A.

SPC Extension Status:

Pending & Published

SPC Extension Grant Date:

SPC Extension Rejection Date:

Marketing Authorization

Marketing Authorization Number:

EU/1/12/793/001-004 - XALKORI - crizotinib

Marketing Authorization Type:

Marketing Authorization Date:

26/10/2012

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

20/02/2013

First Marketing Authorization date:

26/10/2012

Grant date:

22/04/2013

Activation date:

15/08/2025

Publication date:

22/04/2013

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

26/10/2027

SPC Extension Expiration:

26/04/2028

Rejection date:

Withdrawal date:

Owner

From:

14/03/2023

 

 

Name:

PFIZER INC.

Address:

66 Hudson Boulevard East, NY 10001-2192, New York, United States (US)

History of Owners

From:

20/02/2013

To:

14/03/2023

Name:

Pfizer Inc.

Address:

235 East 42nd Street, New York, NY 10017, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

20/02/2013

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

SHEN-Hong Pfizer Global Reserch and Dev.

Address:

United States (US)

2

Name:

TRAN-Dube M. B. , Pfizer Global Reserch and Dev.

Address:

United States (US)

3

Name:

PAIRISH Mason A., Pfizer Global Reserch and Dev.

Address:

United States (US)

4

Name:

JIA Lei, Pfizer Global Reserch and Dev.

Address:

United States (US)

5

Name:

FUNK Lee A., Pfizer Global Reserch and Dev.

Address:

United States (US)

6

Name:

NAMBU Mitchell D., Pfizer Global Reserch and Dev.

Address:

United States (US)

7

Name:

CUI Jingrong J., Pfizer Global Reserch and Dev.

Address:

United States (US)

8

Name:

MENG Jerry J., Pfizer Global Reserch and Dev.

Address:

United States (US)

9

Name:

KUNG Pei-Pei, Pfizer Global Reserch and Dev.

Address:

United States (US)

Publication

Bulletin

1

Bulletin Heading:

SPC4

Bulletin edition number:

2019/02

Publication date:

22/02/2019

Description:

Section F : Correction of granted supplementary protection certificates – I9 publication

2

Bulletin Heading:

CO

Bulletin edition number:

2023/05

Publication date:

04/04/2023

Description:

Section M : Transfers of property (Art. 53 of the law), change of name and/or address

3

Bulletin Heading:

SPC3

Bulletin edition number:

2025/10

Publication date:

05/09/2025

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

4

Bulletin Heading:

SPCX1

Bulletin edition number:

2025/12

Publication date:

07/11/2025

Description:

Section G : Applications for extensions for pediatric use – I1E publication

Deed

Change of owner(s)

Change Kind/ Decision Type:

Change of owner(s) name/address

Deed Number:

RC20230000113A

Date Registered:

14/03/2023

Licence Effective Date:

Licence Expiration Date:

Scope of Licence:

Deed Filer:

OFFICE FREYLINGER S.A.

Journal Edition Number:

Text:

changement d'adresse

Country Code:

Updated Licence Number:

Terminated Licence Number:

Added Owner(s)

Name:

PFIZER INC.

Address:

66 Hudson Boulevard East, NY 10001-2192, New York, United States (US)

Removed Pledgee

Name:

Address:

Annual Fees

Annual Fee Due Date:

31/08/2026

Annual Fee Number:

22

Annual Fee Amount:

420 Euro

Expected Payer:

Last Annual Fee Payment Date:

17/06/2025

Last Annual Fee Paid Number:

21

Last Annual Fee Paid Amount:

410 Euro

Payer:

MASTER DATA CENTER INC (ex Clarivate Analytics)

Filing date	Document type	Number of pages
04/01/2019	Publication	1
16/02/2016	Incoming Correspondence (Post)	3
14/03/2023	Request For Change	1
14/03/2023	Request For Change	1
16/03/2023	Outgoing Correspondence	3
04/01/2019	Outgoing Correspondence	1
01/10/2025	Outgoing Correspondence	1
29/09/2025	Marketing authorization	3
29/09/2025	Outgoing Correspondence	2
29/09/2025	Application Form	5
29/09/2025	General Document	96
29/09/2025	General Document	5
29/09/2025	General Document	1
01/10/2025	Publication	1
01/10/2025	FNET_DC_FRONTPAGE	1